EUVIMEDEUVIMED entdecken
Open Access

Nanocarriers' repartitioning of drugs between blood subcompartments as a mechanism of improving pharmacokinetics, safety, and efficacy

Michael H Zaleski, Serena Omo-Lamai, Jia Nong, Liam S Chase, Jacob W Myerson, Patrick M Glassman, Florence Lee, Sahily Reyes-Esteves, Zhicheng Wang, Manthan N Patel, Alina D Peshkova, Hiroaki Komatsu und 4 weitere

Journal of Controlled Release · 2024-10 · 374 · 425-440

DOI: 10.1016/j.jconrel.2024.07.070 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2024-10. Verfasst von Michael H Zaleski und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Hauptthemen laut MEDLINE: Fingolimod Hydrochloride, Erythrocytes, Liposomes, Drug Carriers. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NINDS NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

For medical emergencies, such as acute ischemic stroke, rapid drug delivery to the target site is essential. For many small molecule drugs, this goal is unachievable due to poor solubility that prevents intravenous administration, and less obviously, by extensive partitioning to plasma proteins and red blood cells (RBCs), which greatly slows delivery to the target. Here we study these effects and how they can be solved by loading into nanoscale drug carriers. We focus on fingolimod, a small molecule drug that is FDA-approved for treatment of multiple sclerosis, which has also shown promise in the treatment of stroke. Unfortunately, fingolimod has poor solubility and very extensive partitioning to plasma proteins and RBCs (in whole blood, 86% partitions to RBCs, 13.96% to plasma proteins, and 0.04% is free). We develop a liposomal formulation that slows the partitioning of fingolimod to RBCs and plasma proteins, enables intravenous delivery, and additionally prevents fingolimod toxicity to RBCs. The liposomal formulation nearly completely prevented fingolimod adsorption to plasma proteins (association with plasma proteins was 98.4 ± 0.4% for the free drug vs. 5.6 ± 0.4% for liposome-loaded drug). When incubated with whole blood in vitro, the liposomal formulation greatly slowed partitioning of fingolimod to RBCs and also eliminated deleterious effects of fingolimod on RBC rigidity, morphology, and hemolysis. In vivo, the liposomal formulation delayed fingolimod partitioning to RBCs for over 30 min, a critical time window for stroke. Fingolimod-loaded liposomes showed improved efficacy in a mouse model of post-stroke neuroinflammation, completely sealing the leaky blood-brain barrier (114 ± 11.5% reduction in albumin leak into the brain for targeted liposomes vs. 38 ± 16.5% reduction for free drug). This effect was only seen for liposomes modified with antibodies to enable targeted delivery to the site of action, and not in unmodified, long-circulating liposomes. Thus, loading fingolimod into liposomes prevented partitioning to RBCs and associated toxicities and enabled targeted delivery. This paradigm can be used for tuning the blood distribution of small molecule drugs for the treatment of acute illnesses requiring rapid pharmacologic intervention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fingolimod HydrochlorideErythrocytesLiposomesDrug CarriersBlood ProteinsAnimalsMaleNanoparticlesImmunosuppressive AgentsMiceMice, Inbred C57BLHumansDrug Delivery Systems

Stichwörter der Autor:innen

Acute critical illnessBlood partitioningNanomedicineRed blood cellsStrokeTargeted drug delivery

Substanzen

Fingolimod HydrochlorideLiposomesDrug CarriersBlood ProteinsImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Pharmacology, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Department of Bioengineering, School of Engineering and Applied Sciences, University of Pennsylvania, Philadelphia, PA, USA.
  • Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, Philadelphia, PA, USA.
  • Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA.
  • Department of Pharmacology, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA.
  • Department of Pharmacology, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: jacob.brenne…

Förderung

  • NHLBI NIH HHS
  • NINDS NIH HHS
  • NIGMS NIH HHS
  • American Heart Association
  • National Institutes of Health

Zitieren

APA

Zaleski, M. H., Omo-Lamai, S., Nong, J., Chase, L. S., Myerson, J. W., Glassman, P. M., Lee, F., Reyes-Esteves, S., Wang, Z., Patel, M. N., Peshkova, A. D., Komatsu, H., Axelsen, P. H., Muzykantov, V. R., Marcos-Contreras, O. A., & Brenner, J. S. (2024). Nanocarriers' repartitioning of drugs between blood subcompartments as a mechanism of improving pharmacokinetics, safety, and efficacy. Journal of Controlled Release, 374, 425-440. https://doi.org/10.1016/j.jconrel.2024.07.070

Vancouver

Zaleski MH, Omo-Lamai S, Nong J, Chase LS, Myerson JW, Glassman PM, et al. Nanocarriers' repartitioning of drugs between blood subcompartments as a mechanism of improving pharmacokinetics, safety, and efficacy. Journal of Controlled Release. 2024;374:425-440. doi:10.1016/j.jconrel.2024.07.070

BibTeX
@article{Zaleski2024,
  author = {Zaleski, Michael H and Omo-Lamai, Serena and Nong, Jia and Chase, Liam S and Myerson, Jacob W and Glassman, Patrick M and Lee, Florence and Reyes-Esteves, Sahily and Wang, Zhicheng and Patel, Manthan N and Peshkova, Alina D and Komatsu, Hiroaki and Axelsen, Paul H and Muzykantov, Vladimir R and Marcos-Contreras, Oscar A and Brenner, Jacob S},
  title = {Nanocarriers' repartitioning of drugs between blood subcompartments as a mechanism of improving pharmacokinetics, safety, and efficacy},
  journal = {Journal of Controlled Release},
  year = {2024},
  volume = {374},
  pages = {425--440},
  doi = {10.1016/j.jconrel.2024.07.070}
}
Kostenlos starten →